Specific targets, such as PRMT1, KDM6B, CARM1, BRD4, and EZH2, have been shown to be associated with malignant phenotypes of lung cancer, influencing cell proliferation and metastatic processes (regulation of epithelial–mesenchymal transition and cell invasion). Here, KDM6B is linked to lung cancer.